Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — September 2017

Planlagt Fastgjort Låst Flyttet Genmab
1.8k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • M Offline
    M Offline
    Mattiw
    wrote on sidst redigeret af
    #288

    Access to this page has been denied

    px-captcha

    favicon

    (seekingalpha.com)

    1 Reply Last reply
    0
    • M Offline
      M Offline
      Mattiw
      wrote on sidst redigeret af
      #289

      Verastem (NASDAQ:VSTM) is up 30% premarket on average volume in response to its announcement of positive results from a Phase 3 clinical trial, DUO, assessing duvelisib compared to ofatumumab (Novartis' ARZERRA) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

      1 Reply Last reply
      0
      • SolsenS Offline
        SolsenS Offline
        Solsen
        wrote on sidst redigeret af
        #290

        Darzalex for lung cancer https://m.indiamart.com/proddetail.php?i=14901049948 ???

        1 Reply Last reply
        0
        • P Offline
          P Offline
          pauly
          wrote on sidst redigeret af
          #291

          Lungekræft? Den var ny, men da det er Indien kan det sikkert være fake medicin

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #292

            Cant remember what Novartis paid for ofatumumab rights, but maybe they should have bought Verastem 😞

            1 Reply Last reply
            0
            • J Offline
              J Offline
              Jedi
              wrote on sidst redigeret af
              #293

              Duvelisib, the Verastem drug, is a PI3K kinase inhibitor https://en.wikipedia.org/wiki/Duvelisib that works in a different way than the CD20 antibody ofatumumab. Novartis likely bought the Arzerra rights due to the potential in MS and not so much in CLL and other cancers where Ibrutinib and other kinase inhibitors see much
              success

              1 Reply Last reply
              0
              • MadsSkjernM Offline
                MadsSkjernM Offline
                MadsSkjern
                wrote on sidst redigeret af
                #294

                Godmorgen. Partial clinical hold på opdivo studier i mm. Går mest ud over elotuzomab, men også dara fase 1 pauseres. Dog fortsætter pt med klinisk respons. https://investors.bms.com/iframes/press-releases/press-release-details/2017/Bristol-Myers-Squibb-Provides-an-Update-on-Three-Opdivo-based-Combination-Clinical-Studies-in-Multiple-Myeloma-/default.aspx

                1 Reply Last reply
                0
                • J Offline
                  J Offline
                  jkj
                  wrote on sidst redigeret af
                  #295

                  Godmorgen

                  1 Reply Last reply
                  0
                  • B Offline
                    B Offline
                    bibob
                    wrote on sidst redigeret af
                    #296

                    God morgen. 🙂

                    1 Reply Last reply
                    0
                    • B Offline
                      B Offline
                      bibob
                      wrote on sidst redigeret af
                      #297

                      Det kan ikke undre at der bliver sat pause på nogle forsøg da der er mange forskellige kombier igang på tværs af Big pharma. Ikke alt er jo lige velegnet at kombinere.

                      1 Reply Last reply
                      0
                      • Helge_LarsenPI-redaktørH Offline
                        Helge_LarsenPI-redaktørH Offline
                        Helge_LarsenPI-redaktør
                        wrote on sidst redigeret af
                        #298

                        God morgen. 🙂

                        1 Reply Last reply
                        0
                        • BulderB Offline
                          BulderB Offline
                          Bulder
                          wrote on sidst redigeret af
                          #299

                          FDA handler hurtigt må man sige. Bliver interessant at se om det først og fremmest er PD-1-blokkerne de er efter og om atezolizumab og Durvalumab går fri.

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Sukkeralf
                            wrote on sidst redigeret af
                            #300

                            Kan huske Jan i begyndelsen af æraen med daratumumab kombi-samarbejde med checkpointinhibitorer sagde, at han så de bedste muligheder med den ene af slagsen PD1 eller PD-L1

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote on sidst redigeret af
                              #301

                              Fandt dog aldrig ud af hvad han var mest tilhænger af - og hvorfor

                              1 Reply Last reply
                              0
                              • BulderB Offline
                                BulderB Offline
                                Bulder
                                wrote on sidst redigeret af
                                #302

                                Oplagt spm til næste Q&A

                                1 Reply Last reply
                                0
                                • B Offline
                                  B Offline
                                  bibob
                                  wrote on sidst redigeret af
                                  #303

                                  Hvilke forsøg kører der med PD1/PD-L1 og Dara , og i hvilke faser ?

                                  1 Reply Last reply
                                  0
                                  • BulderB Offline
                                    BulderB Offline
                                    Bulder
                                    wrote on sidst redigeret af
                                    #304

                                    Søg på ct dara-kombier med atezolizumab, durvalumab, nivolumab og pembrolizumab.

                                    1 Reply Last reply
                                    0
                                    • BulderB Offline
                                      BulderB Offline
                                      Bulder
                                      wrote on sidst redigeret af
                                      #305

                                      Der kører en del både i og uden for MM

                                      1 Reply Last reply
                                      0
                                      • S Offline
                                        S Offline
                                        Sukkeralf
                                        wrote on sidst redigeret af
                                        #306

                                        Bulder har vist spurgt tidligere, men måske tiden er en anden nu

                                        1 Reply Last reply
                                        0
                                        • G Offline
                                          G Offline
                                          gentogen
                                          wrote on sidst redigeret af
                                          #307

                                          Angående duvelisib og CLL er det så ikke en lidt irrelevant sammenligning. Ofatumumab i kombinationer er jo stadig meget bedre for patienterne.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger